Intrinsic Value of S&P & Nasdaq Contact Us

Illumina, Inc. ILMN NASDAQ

NASDAQ Global Select • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
61/100
4/7 Pass
SharesGrow Intrinsic Value
$143.90
+10.4%
Analyst Price Target
$147.13
+12.9%

Illumina, Inc. (ILMN) generated $1.08B in operating cash flow for fiscal year 2025. After capital expenditures of $148M, free cash flow was $931M.

Free cash flow margin was 21.4% of revenue. Cash conversion ratio was 1.27x, indicating earnings are backed by cash.

The company returned $742M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (76/100, Pass) — $931M (21.4% FCF margin) supports a durable competitive advantage
  • INCOME (70/100) — Cash conversion ratio was 1.27x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 61/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
61/100
SG Score
View full scorecard →
VALUE
66/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
52/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
83/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
76/100
Proven by this page
~
GROWTH
58/100
→ Income
INCOME
70/100
→ Income
Illumina, Inc. Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2023
Operating Cash Flow $1.08B$1.08B$837M$478M$478M
Capital Expenditure $-140M$-148M$-128M$-195M$-195M
Free Cash Flow $939M$931M$709M$282M$282M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message